Franklin Resources Inc. Has $748.06 Million Stock Position in Novo Nordisk A/S $NVO

Posted by Brenda Bartman on Jun 9th, 2026

Franklin Resources Inc. increased its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 5.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,702,508 shares of the company’s stock after acquiring an additional 717,719 shares during the quarter. Franklin Resources Inc.’s holdings in Novo Nordisk A/S were worth $748,064,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Capital International Investors increased its holdings in shares of Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after purchasing an additional 6,092,192 shares during the period. Boston Partners acquired a new stake in Novo Nordisk A/S during the third quarter worth about $310,199,000. Clear Street Group Inc. acquired a new stake in Novo Nordisk A/S during the third quarter worth about $56,378,000. Armistice Capital LLC bought a new position in Novo Nordisk A/S during the third quarter valued at about $40,841,000. Finally, Markel Group Inc. raised its holdings in Novo Nordisk A/S by 21.2% in the 4th quarter. Markel Group Inc. now owns 2,869,774 shares of the company’s stock valued at $146,014,000 after acquiring an additional 501,125 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Finally, Wolfe Research began coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating for the company. Four equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $65.56.

Check Out Our Latest Stock Analysis on NVO

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: Novo Nordisk said its oral Wegovy pill has surpassed 3 million U.S. prescriptions in just over five months, suggesting very strong adoption and broadening use among patients who had not previously taken a GLP-1 drug.
Positive Sentiment: Real-world data reportedly show Ozempic 2 mg performing competitively against Eli Lilly’s Mounjaro on glucose control and weight-loss outcomes, which supports Novo’s diabetes franchise. Article: Novo Nordisk Real-World Data Supports Ozempic Against LLY’s Mounjaro
Positive Sentiment: Novo also highlighted investigational zenagamtide data showing 14.6% weight loss in adults with type 2 diabetes, reinforcing optimism around its pipeline. Article: Novo Nordisk’s Investigational Zenagamtide Shows 14.6% Weight Loss In Adults With Type-2 Diabetes
Positive Sentiment: The company continues its share repurchase program, which can help support earnings per share and signals management confidence. Article: Novo Nordisk A/S – share repurchase programme
Neutral Sentiment: Several articles framed Novo and Lilly as locked in a major race for the GLP-1 pill market ahead of Medicare coverage decisions, underscoring the long-term opportunity but also the competitive risk. Article: Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Negative Sentiment: Eli Lilly’s oral GLP-1 pill reportedly outperformed rival therapies in late-stage diabetes trials, highlighting the competitive threat facing Novo Nordisk. Article: LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
Negative Sentiment: Investors also appeared disappointed that Novo’s ADA conference updates did not materially improve the company’s near-term competitive outlook, contributing to the stock’s weakness. Article: Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO)

Novo Nordisk A/S Trading Down 4.4%

Shares of NVO opened at $41.05 on Tuesday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The stock has a market cap of $183.31 billion, a PE ratio of 9.64, a PEG ratio of 3.83 and a beta of 0.78. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The stock has a 50 day simple moving average of $41.71 and a 200-day simple moving average of $46.12.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The firm had revenue of $10.85 billion for the quarter. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.46 EPS for the current fiscal year.

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.